Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03414970 · ClinicalTrials.gov registry record · Phase 3
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
A Phase 3 study of Invasive Breast Carcinoma and Stage II Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 898
- Enrollment target
- 20
- Study locations
NCT03414970 is a Phase 3 study of Invasive Breast Carcinoma and Stage II Breast Cancer that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 898 participants, above the 465-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (93% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT03414970, a Phase 3 study of Invasive Breast Carcinoma and Stage II Breast Cancer, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 898 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- RADIATION Radiation Therapy
- RADIATION Hypofractionated Radiation Therapy
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- PCR Oncology - Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- City of Hope Corona - Corona
- UC Irvine Health Cancer Center-Newport - Costa Mesa
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
- University of Arkansas for Medical Sciences - Little Rock
Arizona
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 898 participants |
| Start Date | 2018-03-12 |
| Est. Completion | 2035-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03414970
The ClinicalTrials.gov registry entry for NCT03414970 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 898 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 465-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (93% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03414970 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alaska, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03414970 about?
NCT03414970 is a clinical study titled "Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer". This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may...
What is the current status of trial NCT03414970?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 898 participants. The study started on 2018-03-12. Estimated completion is 2035-08.
What conditions does trial NCT03414970 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer.
What interventions are being tested in trial NCT03414970?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Radiation Therapy (RADIATION), Hypofractionated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03414970?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03414970 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
RECRUITING · Phase 3
-
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
ACTIVE NOT RECRUITING · Phase 3
-
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.